Lymphatic filariasis, caused by Brugia malayi and others, affects more than 120 million people worldwide causing major public health problems especially in the tropics. Brugia malayi – ALT-2 protein is abundantly synthesized in the infective stages of the parasite and believed to play a major role in the transmission and infectivity of the filarial parasite. […]
| Institute |
|---|
| University of Illinois Chicago |
| Cat. #: | 156378 |
|---|---|
| Unit size: | 100 ug |
| Research Fields: | Immunology;Microbiology |
| Application: | WB ; FACS ; ELISA |
| Target: | Abundant Larval Transcript-2 |
| Host: | Jird |
| Class: | Polyclonal |
| Alternate name: | ALT |
|---|---|
| Product description: | Lymphatic filariasis, caused by Brugia malayi and others, affects more than 120 million people worldwide causing major public health problems especially in the tropics. Brugia malayi – ALT-2 protein is abundantly synthesized in the infective stages of the parasite and believed to play a major role in the transmission and infectivity of the filarial parasite. Bm-alt-2 has several important characteristics of a vaccine candidate. These include high levels of expression in the infective larval stages presenting as an abundant target for the immune system and more importantly there is no known homolog in the mammalian species. |
| Conjugation: | Unconjugated |
| Immunogen: | Recombinant Bm-ALT-2 protein |
| Target background: | Lymphatic filariasis, caused by Brugia malayi and others, affects more than 120 million people worldwide causing major public health problems especially in the tropics. Brugia malayi – ALT-2 protein is abundantly synthesized in the infective stages of the parasite and believed to play a major role in the transmission and infectivity of the filarial parasite. Bm-alt-2 has several important characteristics of a vaccine candidate. These include high levels of expression in the infective larval stages presenting as an abundant target for the immune system and more importantly there is no known homolog in the mammalian species. |
|---|
| Format: | Liquid |
|---|---|
| Shipping conditions: | Dry ice |
| References: |
Thirugnanam et al. 2007. Exp Parasitol. 116(4):483-91. PMID: 17442307. |
|---|
| Cat. # | Tool Name | |||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 151031 | Anti-RuvA [RuvA 12C6] |
Key Info
Anti-RuvA [RuvA 12C6]
|
View Tool | |||||||||||||||||||
| 151037 | Anti-Cdk1 [17 (A17)] |
Key Info
Anti-Cdk1 [17 (A17)]
|
View Tool | |||||||||||||||||||
| 151020 | Anti-CyclinB1 [V143.1] |
Key Info
Anti-CyclinB1 [V143.1]
|
View Tool | |||||||||||||||||||
| 151028 | Anti-Cytochrome P450 2C2, 2B1/2 [h7] |
Key Info
Anti-Cytochrome P450 2C2, 2B1/2 [h7]
|
View Tool | |||||||||||||||||||
| 151018 | Anti-Mos [R38.1] |
Key Info
Anti-Mos [R38.1]
|
View Tool | |||||||||||||||||||
Please note we may take up to three days to respond to your enquiry.
CancerTools.org uses the contact information provided to respond to you about our research tools and service. For more information please review our privacy policy.